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Stroke-induced inflammatory reaction leads to the accumulation of leukocytes
in the brain ischaemic region, where they exert a detrimental effect - promotion
and extension of cerebral damage. Intracerebral infiltration of peripheral blood
leukocytes requires prior endothelial-leukocyte interactions that are mediated
by such cell surface proteins as adhesion molecules. Among adhesion mole-
cules, it is the immunoglobulin gene superfamily (IgSF) that is responsible for
strong attachment and transendothelial migration of leukocytes. The principal
members of IgSF are: intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1) and platelet endothelial cell adhesion molecule-1
(PECAM-1). In this review the following issues were described and discussed: an
increased expression of ICAM-1 and VCAM-1 in ischaemic brain as well as
a detection of their soluble(s) forms in sera of stroke victims. The presented data
suggest the involvement of both ICAM-1 and VCAM-1 in the sequence and
timing of the infiltration of leukocytes into the brain ischaemic zone after stroke.
They have also revealed changes in serum concentrations of sICAM-1 and
sVCAM-1 that are characteristic for stroke. Recently, increase in sPECAM-1 levels
in serum and cerebrospinal fluid (CSF) has been shown within 24 h of the onset
of stroke, having indirectly suggested involvement of the molecule in the inflam-
matory events during the early phase of stroke.
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THE EFFECT OF INFLAMMATION
ON STROKE
Current concepts of the pathomechanism of
stroke indicate the significance of cerebral ischaemia-
induced local inflammatory reaction to the brain
damage. Endotheliocytes of ischaemic brain mi-
crovasculature secrete inflammatory mediators at-
tracting peripheral blood leukocytes to the cere-
brovascular milieu [23, 60]. Adhesion of leukocytes
to the endothelium occludes cerebral capillaries im-
pairing microcirculation [42, 59]. Phospholipase ac-
tivation in leukocytes results in synthesis of prostag-
landins, leukotrienes, eicosanoids, and platelet-acti-
vating factor, which can cause vasoconstriction and
increase platelet aggregation.
Ischaemic brain-infiltrated leukocytes produce
a cohort of biotoxic compounds like proteolytic en-
zymes, toxic oxygen metabolites and cytokines that
contribute to the cerebral tissue injury, including sec-
ondary lesion of the ischaemic neurones [7, 24, 25].
2Folia Morphol., 2002, Vol. 61, No. 1
With regard to the above-mentioned involvement
of inflammatory cells in promotion and extension of
brain ischaemic damage, the central role of endot-
helial-leukocyte interactions mediated by such
bioactive substances as adhesion molecules appears
ever more critical in stroke-induced inflammatory
reaction.
AN OUTLINE OF ADHESION
MOLECULES NATURE
Adhesion molecules are cell surface proteins in-
volved in interactions between cells. They participate
in many biological processes, such as attachment,
proliferation, migration and cellular growth. They are
divided into three primary groups: selectins, immu-
noglobulin gene superfamily (IgSF) and integrins.
Soluble forms of adhesion molecules exist as a result
of proteolytic cleavage from the cell surface and may
be measured in body fluids such as serum or cere-
brospinal fluid (CSF). Adhesion molecules mediate
attachment and transendothelial migration of leuko-
cytes, being an important phenomenon involved in
the inflammatory processes, including stroke-induced
inflammation [2, 8, 24, 45]. Interactions between cell
adhesion molecules of leukocytes and the endothe-
lium in the region of evolving inflammation appear in
the order of sequence [6, 15]. Selectins mediate ini-
tial attachment of flowing leukocytes to the blood
vessel and rolling them along the endothelial surface
[8]. These interactions are transient and reversible and
do not lead to firm adhesion and transendothelial
migration of leukocytes unless members of the IgSF
are involved [15, 58]. Thus, we focused on IgSF, which
— together with their counterparts, i.e. the integrins
— have a key significance in leukocyte adhesion, mi-
gration and brain infiltration in stroke-induced inflam-
matory reaction.
IgSF is the most abundant family of cell surface
molecules, accounting for 50% of leukocyte surface
proteins. Their structure is characterised by repeated
domains, similar to those found in immunoglobu-
lins, built from a tightly packed barrel of beta strands.
By mutation and selection, the Ig domain has evolved
to serve many different functions including: recep-
tors for growth factors; receptors for the Fc region
of Ig; and as adhesion molecules, which now seems
to be the function of the majority [28].
The principal members of IgSF are: intercellular
adhesion molecule-1 (ICAM-1), vascular cell adhe-
sion molecule-1 (VCAM-1) and platelet endothelial
cell adhesion molecule-1 (PECAM-1).
ICAM-1
ICAM-1 is a 90–115 kDa protein expressed in sev-
eral organs, including cerebral endothelium and leu-
kocytes [46]. The expression can be stimulated by such
proinflammatory cytokines as tumour necrosis fac-
tor-alpha (TNF-alpha), interleukin-1-beta (IL-1-beta),
and interferon-gamma (IFN-gamma) [1, 54].
Proinflammatory cytokines TNF-alpha and IL-1-beta
are induced following brain ischaemia earlier than
adhesion molecules [52]. The development of inflam-
matory response in cerebral ischaemia, therefore,
appears to follow the sequence: expression of TNF-
-alpha and IL-1-beta, adhesion molecules cascade, leu-
kocyte adhesion followed by migration [52]. ICAM-1
upregulation in cultured human cerebromicrovascular
endothelial cells has been demonstrated by 4–24 h
exposure to TNF-alpha or IL-1 beta, and by a 4 h ex-
posure to stimulated in vitro ischaemia [48].
ICAM-1 mRNA expression has been shown in
brain microvascular endothelial cells during hypoxia/
/reoxygenation [27]. Upregulation of ICAM-1 in
microvessels in the ischaemic zone of focal brain is-
chaemia has been reported in experimental [38] or
post mortem [46] studies. Clark et al. [12] showed
that the expression of ICAM-1 has been significantly
elevated on the microvasculature within 1 h after
global ischaemia in rats and that this persisted for
several days. They also demonstrated an association
between the time of ICAM-1 brain microvessel ex-
pression and the time of leukocyte subsets infiltra-
tion to the ischaemic forebrain (neutrophils within
the first 24 h and monocytes up to 7 days after is-
chaemia). Lindsberg et al. [31] performed human
brain autopsy study of patients who died within 15 h
to 18 days of an acute stroke, demonstrating ICAM-1
upregulation on microvessels in areas of infarction
by 1.8 days after ischaemia. Moreover, they found
that neutrophils accumulation in the brain infarcted
region was observed as early as 15 h in amounts of
11.3 cells/mm2 compared with 0.5 cells/mm2 in con-
trol areas and exceeded 200 cells/mm2 by 2.2 days,
depicting a correlation between ICAM-1 expression
and leukocyte migration.
These data indicate the involvement of ICAM-1
in the sequence and timing of the infiltration of in-
flammatory cells to the ischaemic brain region after
stroke, which was well documented in both animal
models [30] and in humans [3]. Within hours of ce-
rebral infarction, neutrophils are the first peripheral
blood leukocytes that begin to migrate into the
ischaemic tissue [30] and their response reaches its
3Jarosław Zaremba et al., Adhesion molecules of IgSF in stroke
maximum usually 24–48 h after stroke [3]. An influx
of monocytes begins within 24 h and its maximum
value is observed several days later [30].
Increased sICAM-1 levels have been found in sera
of patients within the first 24 h of stroke in compari-
son with healthy age-matched control individuals
[44]. Bitsch et al. [9] determined serum sICAM-1 lev-
els in patients with cerebral ischaemia at the study
entry (the sudden emergence of a focal neurological
deficit of shorter than or equal to 12 h duration
has been the criterion for inclusion), after 12h, 24 h,
5 days for transient ischaemic attack (TIA), and addi-
tionally after 14 days for stroke. They revealed that in
patients with stroke but not in patients with TIA,
sICAM-1 peaked in serum within 24 h of the onset
of neurological signs. This may reflect the pathoge-
netic differences between these two conditions with
respect to a more prominent endothelial activation
and subsequent molecule expression in stroke com-
pared with TIA.
Fassbender et al. [16] serially measured sICAM-1
levels in sera of stroke patients from 4 h to 5 days
after the disease onset as well as in sera of control
group, which consisted of non-stroke patients with
risk factors for atherosclerosis and healthy subjects.
They reported that concentrations of sICAM-1, already
increased in subjects with vascular risk factors, did
not elevate further in stroke patients. This is consis-
tent with reports of serum increased levels of sICAM-
1 in diabetes mellitus [19, 40] and with a strong
upregulation of ICAM-1 observed in atherosclerotic
vessels [14]. It may indicate involvement of ICAM-1
not only in stroke-induced acute inflammatory reac-
tion but also in chronic endothelial inflammation,
which has appeared already during atherogenesis.
Clark et al. [11] reported decreased serum levels
of sICAM-1 and increased neutrophils adhesion to
laminin (major glycoprotein of endothelial basement
membrane) [56] which is used to attach neutrophils
to collagen [49] in patients with acute (< 72 h after
onset) ischaemic stroke compared with controls or
individuals with vascular risk factors. They hypothesised
that neutrophils in patients with acute stroke may
have a high number of adhesion molecule receptors
and hence a higher degree of sICAM-1 binding. In-
deed, increased adhesiveness of neutrophils was
detected in patients within the first three days of
ischaemic stroke [21].
In genetically engineered mice that lack ICAM-1,
brain infarct volume is significantly reduced after tran-
sient middle cerebral artery occlusion compared with
normal animals [13]. This effect seems to be elicited
with elimination of ICAM-1-mediated adhesion and
transmigration of leukocytes; as Pozzilli et al. [39]
demonstrated, the elevation of peripheral blood leu-
kocytes counts observed after cerebral infarction re-
flected the degree of the inflammatory response in
the acute phase of ischaemic stroke and was related
to the extent of the local cerebral damage measured
with computed tomography of the brain.
VCAM-1
VCAM-1 is a 90–110 kDa protein. In contrast to
ICAM-1, VCAM-1 is absent in resting endothelial cells,
but — similarly to ICAM-1 — can be upregulated by
several proinflammatory cytokines like TNF-alpha,
IL-1-beta or interferon-gamma [43]. Cultured cere-
bral endothelial cells express VCAM-1 after in vitro
stimulation by TNF-alpha and IL-1-beta or simulation
of ischaemia in the manner similar to ICAM-1 [48].
The immunocytochemical study of brain tissue
from patients who died following acute ischaemic
stroke has shown intense expression of VCAM-1 by
endothelial cells and astrocytes from the infarcted,
but not the non-infarcted, areas as well as only weak
expression of ICAM-1 [10, 29]. Moreover, Blann et
al. [10] reported increased serum sVCAM-1 but not
sICAM-1 levels in patients within acute phase of stroke
(the measurements were performed below 12 h from
the onset of neurological signs) compared with
healthy controls and subjects with carotid athero-
sclerosis as well as still high levels at 3-month fol-
low-up. These findings not only suggest VCAM-1
expression and release in both the acute and chronic
stages of ischaemic stroke but they also indicate in-
volvement of VCAM-1 in complex pathophysiologi-
cal responses to infarction and repair of brain tissue
following stroke.
Fassbender et al. [16] reported that patients with
acute stroke displayed significantly increased sVCAM-1
levels in serum compared with subjects with vascu-
lar risk factors. This may reflect acute upregulation
of the molecule during stroke early phase and its
shedding at sites of ischaemic cerebral tissue lesion.
Bearing in mind that VCAM-1 mediate firm adhe-
sion, activation and subsequent passage of leuko-
cytes into the region of evolving inflammation [20,
53], the early increase in sVCAM-1 levels in serum
of stroke patients is in accordance with observa-
tions of the neutrophil extravasation as early as 30
to 60 minutes in microvessels after experimental
middle cerebral artery occlusion [22, 32, 59].
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Fassbender et al. [16] added the remark that the
increase in sVCAM-1 concentrations in serum of
stroke patients observed as early as at 4 h after the
disease onset persisted until day 5. Bitsch et al. [9]
also reported that sVCAM-1 reached a maximal level
in serum of stroke patients 5 days after the onset of
neurological signs. Moreover, they emphasised that
this characteristic peak of sVCAM-1 level in serum
was only found in patients after stroke but not after
TIA. It is consistent with a study performed by Sörnäs
et al.[47], who demonstrated that peak monocyte
accumulation in cerebrospinal fluid (CSF) occurred
between 3 and 7 days after stroke in humans. These
data support a consideration that VCAM-1 may con-
tribute not only to the early infiltration of neutro-
phils into the brain ischaemic region but also to the
second invasion of inflammatory cells, which involves
primarily the migration of monocytes which begin
to invade the brain within 24 h of stroke and reaches
a maximum several days later [30].
PECAM-1
PECAM-1 is a 130-kDa protein constitutively ex-
pressed on endothelial cells, platelets, neutrophils,
monocytes, lymphocytes and basophils [18, 35, 50].
It appears in large amounts as a major constituent
of the endothelial cell intercellular junctions [5, 33,
34], where up to 106 of  PECAM-1 molecules [36]
are concentrated. In contrast to other members of
IgSF, expression of PECAM-1 is not altered by
cytokines TNF-alpha and IL-1-beta treatment [26,
41, 55]. This is in accordance with the concept sug-
gesting that the involvement of PECAM-1 in adhe-
sion molecules cascade depends at least in part on
integrin signalling during endothelial-leukocyte in-
teractions [4, 20].
A number of studies indicate PECAM-1 to be the
molecule directly engaged in the process of
transendothelial migration of leukocytes [35, 37, 50,
51]. Müller et al. [35] were the first to show, in a quan-
titative in vitro assay of transendothelial migration,
that pretreating neutrophils or monocytes with an-
tibodies specific for PECAM-1 inhibited their mi-
gration across the endothelial cell monolayer. They
also showed that blocking endothelial cell junctional
PECAM-1 effectively inhibited leukocyte transmigra-
tion, indicating that PECAM-1 molecules on both the
endothelial cell as well as the leukocyte side contrib-
uted to the transmigration process.
PECAM-1, in contrast to other adhesion mol-
ecules, has an ability to bind to itself [17]. Therefore
the process of transendothelial migration of leuko-
cytes through intercellular junctions of endothelial
cells — where the molecule is largely present — is
mediated at least in part by homophilic adhesive in-
teractions that take place between leukocyte and
endothelial cell junctional PECAM-1 molecules [51].
So far, investigations on PECAM-1 in experimen-
tal animal models of cerebral ischaemia or in inf-
arcted human brain have not been performed. How-
ever, we have recently studied sPECAM-1 levels in
serum and CSF in 23 patients with first-ever in a life-
time completed ischaemic stroke within 24 h of the
onset of neurological signs. Serum and CSF from
15 individuals, who were age- and sex-matched with
the stroke patients, served as a control group, which
consisted of 9 patients diagnosed with tension head-
ache and 6 patients with anxiety neurosis. Stroke
patients displayed statistically significantly higher
levels of sPECAM-1 in sera and CSF in comparison
with control group. Furthermore, the stroke patients
presented significantly higher levels of sPECAM-1 in
sera than in CSF and these levels were correlated
between each other. The results of our study indi-
rectly suggest that PECAM-1 may play a role in the
inflammatory events during the early phase of
ischaemic stroke [57].
CONCLUSIONS
We believe that the data of IgSF so far obtained
from stroke patients depict only a part of events
appearing in stroke-induced inflammatory reaction.
Nevertheless, the data described above indicate the
involvement of IgSF in the pathomechanism of stroke
and show that these dynamically changing molecules
play an important role in the regulation of the in-
flammatory process after stroke.
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